High-risk metastatic gestational trophoblastic disease

Area of Science:

• Gynecology
• Oncology
• Reproductive Medicine

Background:

• Gestational trophoblastic disease (GTD) is a rare pregnancy complication.
• High-risk metastatic GTD presents significant treatment challenges and variable prognoses.

Purpose of the Study:

• To review the clinical course and identify prognostic factors for survival in patients with high-risk metastatic GTD.
• To evaluate the effectiveness of different chemotherapy regimens in this patient population.

Main Methods:

• Retrospective review of clinical data from 61 patients diagnosed with high-risk metastatic GTD.
• Analysis of survival rates based on antecedent pregnancy type, high-risk criteria, and primary chemotherapy regimens.
• Assessment of treatment outcomes for first-line and second-line chemotherapy.

Main Results:

• Overall, 56% of patients achieved complete remission and are alive.
• Survival was significantly worse following a full-term pregnancy compared to other pregnancy types.
• Patients with an elevated beta-human chorionic gonadotropin titer as the sole high-risk criterion had significantly better survival.
• Complete remission rates were 58% with alternating methotrexate and actinomycin-D, and 63% with methotrexate, actinomycin-D, and cyclophosphamide.
• Second-line chemotherapy demonstrated limited success.

Conclusions:

• Aggressive, early multiagent chemotherapy is crucial for managing high-risk metastatic GTD.
• Further research into novel and more effective treatment regimens is warranted.
• Identifying specific high-risk criteria, such as antecedent pregnancy type and hCG levels, aids in prognostic assessment.